首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1735678

2026-2032 年兽医自体疫苗市场：按菌株类型、最终用户和地区划分

Veterinary Autogenous Vaccines Market By Strain Type (Bacterial, Virus), End-User (Veterinary Clinics, Veterinary Hospitals, Veterinary Research Institutes), And Region for 2026-2032

出版日期: 2025年05月02日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

兽医自体疫苗市场评估-2026-2032

对客製化动物保健解决方案的需求不断增长，推动了兽医自体疫苗市场的发展。据 Verified Market Research 分析师称，兽医自体疫苗市场预计在 2024 年价值约为 1.3188 亿美元，预计在预测期内将达到 2.0239 亿美元的估值。

对疾病爆发的日益担忧将推动兽医自体疫苗市场的成长，该市场在 2026 年至 2032 年期间的复合年增长率将达到 5.5%。

自体动物疫苗的市场定义/概述

动物自体疫苗，也称为自身疫苗或自体疫苗，是专门为预防特定地区或农场动物的疾病而量身订做的疫苗。与大量生产用于一般用途的商业疫苗不同，自体疫苗旨在针对特定动物群体的感染疾病。这些疫苗的製备方法是从当地感染的动物体内分离病原体，在受控环境中进行培养，然后针对已识别的感染疾病生产疫苗。

此外，当商业疫苗无法有效或无法有效应对地方性或正在发展的病毒株时，通常会使用自体疫苗接种。自体疫苗常用于牲畜、水产养殖和伴侣动物保健机构，以应对局部疾病爆发，或针对某些动物族群通用疾病进行有针对性的预防。

影响兽医自体疫苗市场成长的驱动因素有哪些？

在全球范围内，动物感染疾病的增加是自体疫苗需求成长的主要驱动力。随着感染疾病的变异和新病毒株的出现，市售疫苗并不总是有效。针对特定动物群体感染的病原体菌株量身定制的自体疫苗，为疾病的控制和预防提供了更有针对性的方案。

标准疫苗并非对所有病原体菌株都有效，尤其是在应对新物种或位特异性突变时。当特定疾病无法透过常规疫苗提供保护时，自我免疫至关重要。这在集约化农业经营中尤其重要，因为疾病的传播可能造成毁灭性后果。

此外，许多地区都制定了法律规范，允许在特定条件下使用自体疫苗，而无需获得完整的上市核准。这种灵活性使兽医和动物卫生专业人员能够快速应对疾病爆发。一些国家的监管机构也认识到自体疫苗在动物健康管理中的重要性，并建议和支持其研究和使用。

兽用自体疫苗市场面临的主要挑战是什么？

畜牧农民和宠物饲主对于自身疫苗接种的好处和可用性缺乏了解。这种缺乏了解，加上对这些疫苗接种的成本和实验性质的担忧，导致他们不愿意采用自身疫苗接种而不是更标准的疫苗，从而阻碍了市场成长。

此外，自体疫苗的生产比常规疫苗更困难、更耗时；必须从每隻动物体内分离病原体，进行培养，并针对具体情况研发疫苗。这种方法不仅需要专门的设备和经验，而且通常产量有限，并根据个体需求进行客製化。将此类疫苗快速运送到所需地点、在运输过程中保持其效力，并确保抵达后正确储存和处理，在物流方面可能面临巨大限制，尤其是在偏远和服务匮乏的地区。

概述
北美洲
- 美国
- 加拿大
- 墨西哥
欧洲
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 其他欧洲国家
亚太地区
- 中国
- 日本
- 印度
- 其他亚太地区
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中东和非洲
- 阿拉伯聯合大公国
- 沙乌地阿拉伯
- 南非
- 其他中东和非洲地区

第八章全球兽用自体疫苗市场竞争格局

概述
各公司市场排名
主要进展
公司地理分布
公司产业足迹
ACE矩阵

第九章公司简介

Boehringer Ingelheim International GmbH
Zoetis Inc.
Gallant Custom Laboratories
Ceva Biovac

第9.8章 SWOT分析

UVAXX
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利条件
- 当前重点和策略
- 竞争威胁
- SWOT分析
Delta动物保健
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利的关键
- 当前重点和策略
- 竞争威胁
- SWOT分析
热那亚研究所
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利的关键
- 当前重点和策略
- 竞争威胁
- SWOT分析
High Gear生物实验室
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利条件
- 当前重点和策略
- 竞争威胁
- SWOT分析
瓦奇诺娃
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利条件
- 当前重点和策略
- 竞争威胁
- SWOT分析
礼来动物保健
- 公司简介
- 企业洞察
- 产品基准
- 主要进展
- 胜利的关键
- 当前重点和策略
- 竞争威胁
- SWOT分析

第十章已验证的市场情报

关于已验证的市场情报
动态资料视觉化

简介目录

Product Code: 35799

Veterinary Autogenous Vaccines Market Valuation - 2026-2032

Growing need for customized animal healthcare solutions propels the Veterinary Autogenous Vaccines Market forward. According to the analyst from Verified Market Research, the Veterinary Autogenous Vaccines Market is estimated to reach a valuation of USD 202.39 Million over the forecast subjugating around USD 131.88 Million valued in 2024.

Rising worries about disease outbreaks drive the growth of the Veterinary Autogenous Vaccines Market. It enables the market to grow at a CAGR of 5.5% from 2026 to 2032.

Veterinary Autogenous Vaccines Market: Definition/Overview

Veterinary autogenous vaccines, also known as autogenous or autologous vaccines, are custom-made vaccines designed to prevent diseases that affect animals in a specific geographic region or farm. Unlike commercial vaccinations, which are mass-produced for general usage, autogenous vaccines are designed to target infections that are peculiar to a particular animal group. These vaccines are created by isolating pathogens from diseased animals on-site, culturing them under controlled settings, and then manufacturing vaccinations that target the identified infections.

Furthermore, autogenous vaccinations are used largely when commercially available vaccines are inefficient or unavailable to address endemic diseases or developing strains. They are frequently employed in cattle farming, aquaculture, and companion animal healthcare settings to combat localized disease outbreaks or to give targeted protection against diseases common in a certain animal group.

What are the Drivers Influencing the Growth of the Veterinary Autogenous Vaccines Market?

The rising occurrence of numerous infectious diseases in animals around the world is a major driver of demand for autogenous vaccines. As infections mutate and new strains emerge, commercial vaccinations may not always be effective. Autogenous vaccinations, which are customized to the individual pathogen strains infecting a given animal population, provide a more targeted approach to disease management and prevention.

Standard vaccines not be effective against all strains of a pathogen, particularly when dealing with novel or region-specific variations. The uniqueness of autogenous vaccinations makes them essential in instances where ordinary vaccines fail to provide protection. This is especially important in intensive farming operations, where disease spread can have disastrous consequences.

Furthermore, many regions have a regulatory framework that allows veterinary autogenous vaccines to be used under certain conditions without requiring full marketing authorization. This flexibility allows veterinarians and animal health specialists to respond quickly to disease outbreaks with tailored remedies. Also, regulatory agencies in several countries have acknowledged the significance of autogenous vaccines in animal health management, giving recommendations and assistance for their research and usage.

What are the Main Challenges Faced by the Veterinary Autogenous Vaccines Market?

There is a shortage of knowledge among livestock farmers and pet owners regarding the benefits and availability of autogenous vaccinations. This lack of understanding, combined with worries about the expense and perceived experimental character of these vaccinations, resulted in reticence to embrace them over more standard vaccines, impeding market growth.

Furthermore, autogenous vaccines are more difficult and time-consuming to manufacture than regular vaccines. It entails isolating pathogens from the individual animals involved, growing them, and then developing a vaccine that is unique to the scenario. This method not only necessitates specialized equipment and experience, but it also implies that production volume is limited and frequently tailored to individual requests. The logistical constraints of providing these vaccines quickly to where they are required, preserving their efficacy during travel, and ensuring correct storage and handling upon arrival can be enormous, particularly in distant or underserved locations.

Category-wise Acumens

What Factors Contribute to the Increasing Demand for Bacterial Strain Vaccine Segment?

According to VMR analyst, the bacterial strain vaccine segment is expected to dominate the segment within the Veterinary Autogenous Vaccines Market during the forecast period. Bacterial infections in animals are common and can cause a wide range of illnesses, including respiratory and gastrointestinal problems, as well as skin and systemic infections. The diversity and prevalence of bacterial infections in livestock and companion animals necessitate the creation and application of bacterial autogenous vaccines. These vaccinations are critical in instances where commercial vaccines are ineffective against specific strains or varieties of bacteria that have arisen within a given herd or geographic area.

Bacteria have rapid mutation rates, which allows them to evolve swiftly and, in some cases, develop antibiotic resistance. This resistance complicates the management of bacterial illnesses, making immunization a more significant technique. Autogenous vaccines, which are tailored to specific strains of bacteria that pose a threat to a herd or group of animals, provide a targeted way to address antimicrobial resistance challenges.

Furthermore, bacterial autogenous vaccines can be produced more easily than viral vaccinations because bacteria may be grown in a variety of growth mediums. This flexibility enables quick vaccine development and distribution in response to epidemics. The specificity of bacterial autogenous vaccines ensures that they are effective against the specific strains causing disease in an animal population, giving them a significant advantage over broad-spectrum commercial vaccinations, which may not cover all strains.

What Factors Contribute to the Dominance of Veterinary Clinics in the Market?

The veterinary clinics segment is estimated to hold the largest share of the Veterinary Autogenous Vaccines Market during the forecast period. Veterinary clinics are the primary healthcare providers for animals, delivering a wide range of treatments from routine check-ups to emergency care. This close and regular connection with animals puts veterinary clinics in a unique position to discover specific health conditions that may necessitate the use of autogenous vaccinations. They can respond promptly to disease outbreaks within a certain herd or area by enabling the creation and distribution of these personalized vaccines.

Veterinary clinics are well positioned to benefit from autogenous vaccinations because of their intimate interaction with both animals and their owners. They have a complete health history and specialized knowledge of illness incidence in their area, which allows them to detect when commercial vaccines are insufficient and tailored remedies are required. This capacity to provide bespoke vaccine solutions broadens their service offering, catering to clients looking for the most effective disease prevention tactics for their animals.

Furthermore, unlike larger institutions or research facilities, veterinary clinics have the freedom to make swift judgments about the health management techniques they apply, such as the use of autogenous vaccinations. They can quickly work with autogenous vaccine makers to meet a pressing requirement, ensuring a prompt response to disease outbreaks. This agility improves their ability to safeguard animal health and limit disease transmission, which contributes greatly to their market dominance for these vaccines.

Country/Region-wise Acumens

How will the Demand for Veterinary Autogenous Vaccines Impact the Asia Pacific region?

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The region has experienced multiple high-profile animal disease outbreaks, including African Swine Fever (ASF) and Avian Influenza. These outbreaks highlight the limitations of traditional vaccinations and the need for more targeted vaccination regimens that can target specific disease strains. Autogenous vaccinations, which are tailored to the diseases afflicting a specific herd or flock, provide a viable answer to this problem, boosting their use.

Furthermore, the livestock sector in Asia Pacific is rapidly expanding, owing to rising demand for animal protein among the region's growing population. Countries such as China, India, and Southeast Asia are seeing fast expansion in the poultry, swine, and cattle industries. This development needs improved disease management tactics to safeguard animal health and productivity, driving demand for personalized vaccine solutions such as autogenous vaccines, especially in intensive agricultural operations where disease outbreaks are more likely.

Which Factors Contributes to the Market Dominance in North America?

North America is estimated to dominate the Veterinary Autogenous Vaccines Market during the forecast period. North America, particularly the United States and Canada, has a well-developed veterinary healthcare infrastructure. This comprises a huge number of veterinary clinics and hospitals with superior diagnosis and treatment capabilities, as well as a robust network of veterinary research institutions. The complex veterinary healthcare system promotes the research, approval, and use of new therapies and vaccines, including autogenous vaccinations, to meet the region's distinct animal population demands.

Furthermore, the region has a strong livestock industry and a high percentage of companion animal ownership, which drives the demand for veterinary services, particularly immunization. The necessity to protect these animals from disease outbreaks, particularly in dense farming operations or regions where animals come into close contact with one another, emphasizes the importance of customized medicine approaches such as autogenous vaccinations. These vaccinations are especially useful in managing disease outbreaks that cannot be efficiently managed with conventional immunizations.

Competitive Landscape

The Veterinary Autogenous Vaccines Market is highly competitive, with competitors ranging from small-scale local manufacturers to major global enterprises. Also, market participants are eager to improve their production capacity and invest in innovative manufacturing technologies to ensure vaccine scalability and efficiency.

Some of the prominent players operating in the Veterinary Autogenous Vaccines Market include:

Boehringer Ingelheim International GmbH, Zoetis Inc., Gallant Custom Laboratories, Ceva Biovac, Dyntec sro, UVAXX Pte Ltd, Deltamune Animal Health, Genova Labs, Hygieia Biological Laboratories, Vaxxinova, Elanco Animal Health, Addison Biological Laboratory, Phibro Animal Health Corporation, Lohmann Tierzucht, Aquatic Biologicals, Ridgeway Biologicals.

Latest Developments:

In February 2023, Gallant Custom Laboratories announced a collaboration with a technology company to create an automated system for autogenous vaccine manufacturing. This could increase efficiency and accessibility.

1 INTRODUCTION OF GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET

1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

2.1 Data Mining
2.2 Data Triangulation
2.3 Bottom-Up Approach
2.4 Top-Down Approach
2.5 Research Flow
2.6 Key Insights from Industry Experts
2.7 Data Sources

3 EXECUTIVE SUMMARY

3.1 Market Overview
3.2 Ecology Mapping
3.3 Absolute Market Opportunity
3.4 Market Attractiveness
3.5 Global Veterinary Autogenous Vaccines Market Geographical Analysis (CAGR %)
3.6 Global Veterinary Autogenous Vaccines Market, By Strain Type (USD Million)
3.7 Global Veterinary Autogenous Vaccines Market, By End-User (USD Million)
3.8 Future Market Opportunities
3.9 Global Market Split
3.10 Product Life Line

4 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET OUTLOOK

4.1 Global Veterinary Autogenous Vaccines Evolution
4.2 Drivers
- 4.2.1 Driver1
- 4.2.2 Driver 2
4.3 Restraints
- 4.3.1 Restraint1
- 4.3.2 Restraint 2
4.4 Opportunities
- 4.4.1 Opportunity1
- 4.4.2 Opportunity 2
4.5 Porters Five Force Model
4.6 Value Chain Analysis
4.7 Pricing Analysis
4.8 Macroeconomic Analysis

5 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY SRAIN TYPE

5.1 Overview
5.2 Bacterial Strain
5.3 Virus Strain

6 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY END-USER

6.1 Overview
6.2 Veterinary Hospitals
6.3 Veterinary Clinics
6.4 Veterinary Research Institutes
6.5 Others

7 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Italy
- 7.3.5 Spain
- 7.3.6 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Latin America
- 7.5.1 Brazil
- 7.5.2 Argentina
- 7.5.3 Rest of Latin America
7.6 Middle-East and Africa
- 7.6.1 UAE
- 7.6.2 Saudi Arabia
- 7.6.3 South Africa
- 7.6.4 Rest of Middle-East and Africa

8 GLOBAL VETERINARY AUTOGENOUS VACCINES MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Developments
8.4 Company Regional Footprint
8.5 Company Industry Footprint
8.6 ACE Matrix

9 COMPANY PROFILES

9.1 Boehringer Ingelheim International GmbH
- 9.1.1 Company Overview
- 9.1.2 Company Insights
- 9.1.3 Product Benchmarking
- 9.1.4 Key Development
- 9.1.5 Winning Imperatives
- 9.1.6 Current Focus & Strategies
- 9.1.7 Threat from Competition
- 9.1.8 SWOT Analysis
9.2 Zoetis Inc.
- 9.2.1 Company Overview
- 9.2.2 Company Insights
- 9.2.3 Product Benchmarking
- 9.2.4 Key Development
- 9.2.5 Winning Imperatives
- 9.2.6 Current Focus & Strategies
- 9.2.7 Threat from Competition
- 9.2.8 SWOT Analysis
9.3 Gallant Custom Laboratories
- 9.3.1 Company Overview
- 9.3.2 Company Insights
- 9.3.3 Product Benchmarking
- 9.3.4 Key Development
- 9.3.5 Winning Imperatives
- 9.3.6 Current Focus & Strategies
- 9.3.7 Threat from Competition
- 9.3.8 SWOT Analysis
9.4 Ceva Biovac
- 9.4.1 Company Overview
- 9.4.2 Company Insights
- 9.4.3 Product Benchmarking
- 9.4.4 Key Development
- 9.4.5 Winning Imperatives
- 9.4.6 Current Focus & Strategies
- 9.4.7 Threat from Competition

9..8 SWOT Analysis

9.5 UVAXX Pte Ltd
- 9.5.1 Company Overview
- 9.5.2 Company Insights
- 9.5.3 Product Benchmarking
- 9.5.4 Key Development
- 9.5.5 Winning Imperatives
- 9.5.6 Current Focus & Strategies
- 9.5.7 Threat from Competition
- 9.5.8 SWOT Analysis
9.6 Deltamune Animal Health
- 9.6.1 Company Overview
- 9.6.2 Company Insights
- 9.6.3 Product Benchmarking
- 9.6.4 Key Development
- 9.6.5 Winning Imperatives
- 9.6.6 Current Focus & Strategies
- 9.6.7 Threat from Competition
- 9.6.8 SWOT Analysis
9.7 Genova Labs
- 9.7.1 Company Overview
- 9.7.2 Company Insights
- 9.7.3 Product Benchmarking
- 9.7.4 Key Development
- 9.7.5 Winning Imperatives
- 9.7.6 Current Focus & Strategies
- 9.7.7 Threat from Competition
- 9.7.8 SWOT Analysis
9.8 Hygieia Biological Laboratories
- 9.8.1 Company Overview
- 9.8.2 Company Insights
- 9.8.3 Product Benchmarking
- 9.8.4 Key Development
- 9.8.5 Winning Imperatives
- 9.8.6 Current Focus & Strategies
- 9.8.7 Threat from Competition
- 9.8.8 SWOT Analysis
9.9 Vaxxinova
- 9.9.1 Company Overview
- 9.9.2 Company Insights
- 9.9.3 Product Benchmarking
- 9.9.4 Key Development
- 9.9.5 Winning Imperatives
- 9.9.6 Current Focus & Strategies
- 9.9.7 Threat from Competition
- 9.9.8 SWOT Analysis
9.10 Elanco Animal Health
- 9.10.1 Company Overview
- 9.10.2 Company Insights
- 9.10.3 Product Benchmarking
- 9.10.4 Key Development
- 9.10.5 Winning Imperatives
- 9.10.6 Current Focus & Strategies
- 9.10.7 Threat from Competition
- 9.10.8 SWOT Analysis

10 VERIFIED MARKET INTELLIGENCE

10.1 About Verified Market Intelligence
10.2 Dynamic Data Visualization

02-2729-4219

+886-2-2729-4219

License/价格